{"id":39036,"date":"2024-06-19T10:25:54","date_gmt":"2024-06-19T10:25:54","guid":{"rendered":"https:\/\/ibima.eu\/?p=39036"},"modified":"2024-06-19T10:25:57","modified_gmt":"2024-06-19T10:25:57","slug":"the-role-of-autoreactive-t-cells-and-ige-autoantibodies-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/the-role-of-autoreactive-t-cells-and-ige-autoantibodies-in-atopic-dermatitis\/","title":{"rendered":"The role of autoreactive T cells and IgE autoantibodies in atopic dermatitis"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb hover_enabled=\u00bb0″ sticky_enabled=\u00bb0″]<\/p>\n

Financed by<\/strong>: Fonds Wetenschappelijk Onderzoek (FWO)<\/span><\/p>\n

Rol in the project:\u00a0<\/strong>Partner<\/span><\/p>\n

Project ID:<\/span>\u00a0<\/b>G056322N<\/a><\/span><\/p>\n

Duration:\u00a0<\/b>January 2021 to December 2025<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Contact:<\/strong>\u00a0Eguiluz Garc\u00eda, Ibon<\/span><\/p>\n

Implementation centre:<\/strong>\u00a0<\/span>Hospital Regional Universitario de M\u00e1laga<\/a><\/span><\/p>\n

Research group of IBIMA involved:<\/strong><\/span>\u00a0Drug and Allergen Allergic Diseases<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_post_title title=\u00bboff\u00bb meta=\u00bboff\u00bb admin_label=\u00bbT\u00edtulo de publicaci\u00f3n\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bbArial||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#2ea3f2″ title_font_size=\u00bb35px\u00bb background_color=\u00bbRGBA(255,255,255,0)\u00bb use_background_color_gradient=\u00bbon\u00bb background_image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2024\/06\/MyDiaMate.png\u00bb text_orientation=\u00bbcenter\u00bb width=\u00bb100%\u00bb max_width=\u00bb97%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb10%||1%||false|false\u00bb hover_enabled=\u00bb0″ title_font_size_last_edited=\u00bboff|desktop\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb sticky_enabled=\u00bb0″][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbABSTRACT\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb hover_enabled=\u00bb0″ sticky_enabled=\u00bb0″]<\/p>\n

In patients with atopic dermatitis (AD), increased risk of co-morbid autoimmune diseases was found. Additionally, IgE-mediated autoimmunity directed to the skin has been demonstrated in patients with moderate\/severe AD, suggesting a role for autoreactive IgE antibodies and self-reactive T cells in AD pathophysiology and an association with disease severity. Previously, we measured IgE-autoreactivity in serum samples using a newly established immunoassay. In the present project, we hypothesize that autoreactive IgE antibodies can be present or develop already shortly after birth, and that IgE autoantibodies levels correlate with disease activity. The project aims at investigating the very first stages of IgE-mediated autoimmunity in new-borns in relation to AD-development, heredity and environmental exposure. Next, we aim to explore the effect of systemic treatment on autoreactive IgE antibody levels and to evaluate the relation with disease activity. Finally, we presume that modulation of the PD-1\/PD-L1 axis could be a potential target for therapy in these patients. Ultimately, we aim to modulate the PD-1\/PD-L1 axis as novel target for therapy in a mouse model. This project will increase current insights of AD-pathophysiology with IgE-mediated autoimmunity and open new doors for disease endotyping and precision therapy with direct consequences for diagnosis and treatment of patients with AD and IgE autoimmunity.<\/span><\/p>\n

[\/et_pb_text][et_pb_heading title=\u00bbPartners\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb hover_enabled=\u00bb0″ sticky_enabled=\u00bb0″ custom_margin=\u00bb20px||||false|false\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb hover_enabled=\u00bb0″ sticky_enabled=\u00bb0″]<\/p>\n